Egr-1 Induces a Profibrotic Injury/Repair Gene Program Associated with Systemic Sclerosis by Bhattacharyya, Swati et al.
Egr-1 Induces a Profibrotic Injury/Repair Gene Program
Associated with Systemic Sclerosis
Swati Bhattacharyya
1*, Jennifer L. Sargent
2, Pan Du
3, Simon Lin
3, Warren G. Tourtellotte
4, Kazuhiko
Takehara
5, Michael L. Whitfield
2, John Varga
1*
1Division of Rheumatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America, 2Department of Genetics, Dartmouth
Medical School, Hanover, New Hampshire, United States of America, 3Northwestern University Clinical and Translational Sciences Institute, Chicago, Illinois, United States
of America, 4Departments of Pathology and Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America, 5Department
of Dermatology, Kanazawa University, Kanazawa, Japan
Abstract
Transforming growth factor-ß (TGF-ß) signaling is implicated in the pathogenesis of fibrosis in scleroderma or systemic
sclerosis (SSc), but the precise mechanisms are poorly understood. The immediate-early gene Egr-1 is an inducible
transcription factor with key roles in mediating fibrotic TGF-ß responses. To elucidate Egr-1 function in SSc-associated
fibrosis, we examined change in gene expression induced by Egr-1 in human fibroblasts at the genome-wide level. Using
microarray expression analysis, we derived a fibroblast ‘‘Egr-1-responsive gene signature’’ comprising over 600 genes
involved in cell proliferation, TGF-ß signaling, wound healing, extracellular matrix synthesis and vascular development. The
experimentally derived ‘‘Egr-1-responsive gene signature’’ was then evaluated in an expression microarray dataset
comprising skin biopsies from 27 patients with localized and systemic forms of scleroderma and six healthy controls. We
found that the ‘‘Egr-1 responsive gene signature’’ was substantially enriched in the ‘‘diffuse-proliferation’’ subset comprising
exclusively of patients with diffuse cutaneous SSc (dcSSc) of skin biopsies. A number of Egr-1-regulated genes was also
associated with the ‘‘inflammatory’’ intrinsic subset. Only a minority of Egr-1-regulated genes was concordantly regulated by
TGF-ß. These results indicate that Egr-1 induces a distinct profibrotic/wound healing gene expression program in fibroblasts
that is associated with skin biopsies from SSc patients with diffuse cutaneous disease. These observations suggest that
targeting Egr-1 expression or activity might be a novel therapeutic strategy to control fibrosis in specific SSc subsets.
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Introduction
Systemic sclerosis (SSc) is a complex disease of unknown cause
with variable clinical manifestation, substantial molecular hetero-
geneity and unpredictable course [1]. While vascular injury and
autoimmunity are prominent in early disease, fibrosis ultimately
develops in most patients, and is responsible for organ failure and a
poor prognosis. Transforming growth factor-ß (TGF-ß) serves as a
potent stimulus for collagen gene transcription, myofibroblast
differentiation, and other fibrotic responses [2]. Since TGF-ß
expression and activity are deregulated in SSc, TGF-ß is considered
a major factor contributing to pathogenesis [3]. Precise delineation
of transcription factors and cofactors that comprise the fibroblast-
specific intracellular TGF-ß signal transduction pathways is
indispensable for developing effective anti-fibrotic therapies [4].
The immediate-early gene product Egr-1 is a zinc finger trans-
cription factor induced by environmental stress, developmental
signals, cytokines, growth factors, hypoxia and oxidative stress [5].
We recently demonstrated that TGF-ß stimulates Egr-1 mRNA
and protein expression in normal fibroblasts in a rapid and
transient manner [6,7]. Moreover, TGF-ß-induced stimulation of
collagen gene expression in these cells was found to be mediated
by Egr-1, which was on its own capable of inducing COL1A2
transactivation, indicating a vital functional role in profibrotic
TGF-ß-responses. Indeed, Egr-1 expression was found to be
elevated in lesional skin tissues from mice with bleomycin-induced
scleroderma, as well as in skin and lung biopsies from patients with
diffuse cutaneous SSc [7]. Together, these observations indicate a
novel functional role for Egr-1 in the regulation of connective
tissue homeostasis, and suggest that abnormal sustained Egr-1
expression might contribute to progression of fibrosis in SSc.
To better understand the implications of Egr-1 activity in the
context of fibrosis, we examined gene regulation by Egr-1 in
primary human skin fibroblasts at the genome-wide level.
Transcriptional profiling by DNA microarray analysis identified
647 genes whose expression in fibroblasts was significantly
changed by Egr-1. These genes are involved in cell proliferation,
TGF-ß signaling, wound healing, extracellular matrix synthesis
and vascular development. Querying a microarray-based gene
expression dataset from skin biopsies from patients with localized
and systemic forms of scleroderma and healthy controls showed
that the ‘‘Egr-1-regulated gene signature’’ was most prominent in
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23082skin biopsies clustering within the ‘‘diffuse-proliferation’’ intrinsic
subsets of SSc biopsies, but some of the genes were also associated
with ‘‘inflammatory’’ subset. These results indicate that Egr-1
exerts potent regulatory effects on a substantial number of
fibroblast genes that are functionally implicated in matrix
remodeling, tissue repair and pathological fibrosis. The Egr-1-
regulated gene signature only partially overlapped with TGF-ß-
regulated genes in fibroblasts, and was most prominent in skin
biopsies from patients with diffuse cutaneous SSc, implicating Egr-
1-mediated fibroblast activation in these patients. These findings
point to a previously unrecognized role for Egr-1 in the
pathogenesis of SSc, and raise the possibility that blocking
excessive Egr-1 signaling might be a potential therapeutic strategy
to control fibrosis.
Materials and Methods
Cell culture and reagents
Cultures of human primary fibroblasts were established by
explantation from neonatal foreskin and studied at early (,8)
passage [8]. Cultures were maintained in modified Eagle’s
medium (EMEM) supplemented with 10% fetal calf serum (FCS)
(Gibco BRL, Grand Island, NY), 1% vitamin solutions, and 2 mM
L-glutamine. All other tissue culture reagents were from Biowhit-
taker (Walkersville, MD). In some experiments, fibroblasts were
incubated with TGF-ß1 (PeproTech, Rocky Hill, NJ) for up to
48 h.
Immunohistochemistry
Skin biopsies from the lesional forearm from six patients with
SSc and three healthy adults were obtained under protocols
approved by the Institutional Review Boards for Human Studies
at Northwestern University or Kanazawa University. Four mm
thick paraffin-embedded skin sections were deparaffinized,
rehydrated and immersed in TBS-T buffer (Tris-buffered saline-
0.1%Tween 20) followed by target retrieval solution (DAKO,
Carpinteria, CA). Following incubation of the slides with primary
antibodies against Egr-1 (Santa Cruz, 1:100 dilution), cartilage
oligomeric matrix protein (COMP) (Accurate Chemical &
Scientific; Westbury, MY; dilution 1:50), E2F7 (Abcam; Cam-
bridge, MA; dilution; 1:200) or GDF6 (Epitomics; Burlingame,
CA; dilution 1:50), bound antibodies were detected using DAKO
Envision+System. After counterstaining with hematoxylin, sections
were mounted with Permount (Fisher Scientific, Pittsburgh, PA)
and viewed under a Nuance Multiple Spectra microscope.
Infection with adenovirus
Adenoviral recombinants containing active Egr1 that does not
contain the NAB inhibitory domain mutant of Egr-1 (Ad-Egr-1m)
[9], and Ad-EGFP expressing the green fluorescent protein (GFP)
were amplified and used for infecting human fibroblasts. At early
confluence, fibroblasts in serum-free media were infected with
adenovirus (100 MOI). Following 24–48 h incubation, cells were
harvested, total RNA or whole cell lysates were isolated, and
processed for microarray, real-time quantitative PCR or Western
analysis.
Microarray procedures
For genome-wide analysis of the Egr-1 response, confluent
fibroblasts in 100 mm dishes were cultured in to serum-free
media immediately prior to adenovirus infection. Total RNA was
isolated from two independent fibroblast cultures for each time
point (24 and 48 h) using RNeasy mini kit (Qiagen, Valencia,
CA). The integrity of RNA was ascertained by an Agilent
Bioanalyzer (Santa Clara, CA). cDNA was labeled using an
Ambion labeling kit (Ambion) and was hybridized to Illumina
Human Ref-6 version 2 Expression Microarray Chips (Illumina,
San Diego, CA).
Data Analysis
Raw signal intensities for each probe were obtained using
Illumina Beadstudio data analysis software and imported to the
Bioconductor lumi package for data transformation and normal-
ization [10,11]. The data were preprocessed using variance
stabilization transformation method [12] followed by quantile
normalization. Probes with all samples ‘‘absent’’ (near or below
background levels) were filtered. The rest of the probes were used
for further analysis. Differential analysis was performed using
Bioconductor limma package [13]. The variance used in the t-
score calculation was corrected by an empirical Bayesian method
for better estimation with a small sample size [13]. To control the
effects of multiple testing and reduce the false positive rate (FDR),
stringent statistical criteria were used to identify differentially
expressed genes with p values less than 0.01 and fold-induction.2
fold [14]. Comparisons of data for Egr-1m versus control and
TGF-ß versus control were performed separately by Ingenuity
Pathway Analysis (Ingenuity, Mountain View, CA).
The microarray dataset of skin biopsies from 27 patients with
various forms of scleroderma and healthy controls, was down-
loaded from the UNC Microarray Database and is also available
from GEO (Accession GSE9285). This dataset has been described
in detail [15].
Real-time quantitative PCR
Total RNA (50 ng) was reverse-transcribed to cDNA using
Reverse Transcription System (Promega, Madison, WI) [7]. The
products were amplified using SYBR Green PCR Master Mix
(Applied Biosytems, Foster City, CA) on the Applied Biosystems
7500 Prism Sequence Detection System. The primers used are
shown in Table 1.
Table 1. Oligonucleotides used as primers for Real-Time
Quantitative PCR.
TIMP3 Forward 59CCTTTGGCACTCTGGTCTACA39
Reverse 59GTCCCACCTCTCCACAAAGTT39
COMP Forward 59 AGC ACC GGC CCC AAG T 39
Reverse 59 GGT TGT GCC AAG ACC ACG TT39
KIAA1199 Forward 59 GTG AGC CAC ACG AGC TTC AG39
Reverse 59 GGA TGG TCG CCA CATAGT TGA39
MMP3 Forward 59 ACA AAG GAT ACA ACA GGG ACC AA39
Reverse 59 TAG AGT GGG TAC ATC AAA GCT TCA GT39
PDGFC Forward 59 CAA GGA ACA GAA CGG AGT ACA AGA39
Reverse 59 CCA TAC ATT TTC CTCTAC TGC TAC TAA
TCT39
BGN Forward 59 TGTTCCCTCCATCTCTCCGAACCTG 39
Reverse 59 GACCGCTGTCCCTGGGGTTTTG39
FN Forward 59 GCCTGGTACAGAATATGTAGTG39
Reverse 59 ATCCCAGCTGATCAGTAGGCTGGTG39
PLOD2 Forward 59 CAGAAGGAACAGCTGGGAGTG39
Reverse 59 GTGGTGACTGCGAGGGCTT39
doi:10.1371/journal.pone.0023082.t001
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At the end of each experiment, cultures were harvested, whole
cell lysates were isolated and equal amounts of proteins (20–
50 mg/lane) were subjected to electrophoresis in 4–15% SDS
polyacrylamide gradient gels [7]. Proteins were transferred to
Immobilon-P membranes (Millipore, Billerica, MA) and mem-
branes were probed sequentially with primary antibodies specific
for Egr-1 (C19), actin (C2) (both from Santa Cruz Biotechnology,
Santa Cruz, CA) or Type I collagen (Southern Biotech, Birming-
ham, AL). Membranes were then incubated with appropriate
secondary antibodies and subjected to enhanced chemilumines-
cence detection using ECL reagent (Amersham-Pharmacia,
Piscataway, NJ).
Statistical Methods
Statistical significance for real-time qPCR results was deter-
mined using the unpaired Student’s t-test. A p value,0.05 was
considered significant.
Data access
Microarray data have been deposited at GEO (http://www.
ncbi.nlm.nih.gov/geo/; accession no. GSE27165 (provisional). All
data are MIAME compliant.
Results
Adenoviral-Egr-1infection results in Egr-1 overexpression
in skin fibroblasts
To define optimal experimental condition, we first examined
the effects of Egr-1 or a transcriptionally active Egr1 that is
refractory to it endogenous inhibitor Nab2 [16]. Normal skin
fibroblasts were infected in parallel with indicated concentrations
of Ad Egr-1 or AdEgr-1m or the control vector Ad-EGFP and
incubated for various periods up to 48 h. Ectopic Egr-1 expression
in infected fibroblasts resulted in a ,6-fold increase in the cellular
abundance of Egr-1 (Fig. 1A), which is comparable to the magni-
tude of increase in Egr-1 induced by TGF-ß [6]. Accumulation of
Egr-1 in infected fibroblasts was accompanied by marked
stimulation of Type I collagen synthesis. As expected, Egr-1m
elicited a more robust stimulatory response than wildtype Egr-1,
since resistance to Nab2 in this Egr-1 mutant permitted unfettered
target gene stimulation. Immunofluorescence analysis confirmed
maximal Egr-1 expression at 48 h in fibroblasts infected with 100
MOI Ad-EGFP (Fig. 1B). No effect on cell viability was detected
under these conditions.
Identification of Egr-1 target genes by Illumina
Microarray analysis
To evaluate gene expression changes induced by Egr-1 at the
genome-wide level, confluent skin fibroblasts were infected with
Ad-Egr-1m for up to 48 h and total RNA processed for
microarray analysis. To reduce the false positive rate, probes with
all samples ‘‘Absent’’ were filtered for further analysis, leaving
12915 probes. Gene expression in Egr1m-infected fibroblasts was
compared to that of Ad-EGFP-infected fibroblasts at each time
point, duplicate samples for each time point showed similar
changes in gene expression patterns. Probes that showed a .2-fold
change in Egr-1m-infected fibroblasts compared to control-
infected cultures at each time point were selected for further
analysis. At 24 h 235 genes showed significantly altered expression
(p,10
25; FDR,0.01), with 109 genes showing increased expre-
ssion and 126 genes decreased expression (Fig. 2A). At 48 h, 647
genes demonstrated significantly altered expression, with 261
genes increased and 386 genes decreased. This 647-gene cohort
was defined as the fibroblast ‘‘Egr-1-responsive gene signature’’.
The top Egr-1-regulated genes at 24 h and 48 h (p,0.001) are
shown in Tables S1 and S2.
Genome-wide responses to Egr-1
To identify biological processes enriched significantly (p,0.001;
Hyper-geometric test) with Egr-1-regulated genes, GO analysis
was performed (Fig. 2B). The list of enriched biological processes
includes cell proliferation, cell migration, extracellular matrix
synthesis, wound healing, vascular development and TGF-ß
receptor signaling, all of which are known to be implicated in
wound healing, tissue remodeling and fibrosis. A time-dependent
increase in the number of genes associated with each biological
process was observed. GO analysis confirmed that Egr-1 induced a
time-dependent ECM gene expression program, with the number
of ECM genes increasing .2.5-fold (from 16 to 41) between 24
and 48 h. Genes in this group include those coding for multiple
collagens (COL4A1, COL4A2, COL11A1, COL7A1, COL10A1),
biglycan, fibronectin, COMP, procollagen-lysine, 2-oxoglutarate
5-dioxygenase2 (PLOD2), and tissue inhibitor of matrix metallo-
proteinase 3 (TIMP3). The observed pattern of Egr-1-induced
changes in gene expression therefore is consistent with the notion
that persistent Egr-1 signaling in fibroblasts induces tissue
remodeling, wound healing and fibrogenesis gene program.
Validation of the ‘‘Egr-1-responsive gene signature’’ in
fibroblasts
Real-time qPCR was used to validate Egr-1-induced changes in
fibroblasts ECM gene expression. For this purpose, RNA from the
same samples that were used for DNA microarrays were subjected
to further analysis by real-time qPCR. The changes in the
expression of eight Egr-1-induced ECM genes were compared
to the expression from the DNA microarrays. In each case,
expression changes determined by the real-time qPCR showed the
same direction of change as was seen in microarray analysis
(Fig. 2C, and data not shown).
Overlap of the Egr-1-regulated gene signature and the
TGF-ß-regulated gene signature
Because TGF-ß induces a robust time-dependent up-regulation
of Egr-1 along with numerous profibrotic genes [17,18], and since
Egr-1 itself plays a role in mediating TGF-ß-mediated fibrotic
responses [6,7], we sought to compare response induced by Egr-1
and by TGF-ß in normal fibroblasts at the genome-wide level
using microarrays. Analysis of the data showed that while at 48 h
Figure 1. Adenovirus-mediated Egr-1 expression in human skin
fibroblasts. Confluent dermal fibroblasts were infected with Ad-EGFP,
Egr-1 or Egr-1m (100 MOI) for 48 h. A. Cultures were harvested and
whole cell lysates were subjected to Western analysis. Representative
immunoblots. B. Fibroblasts were examined by fluorescence microsco-
py. Representative image. (Original magnification 6400).
doi:10.1371/journal.pone.0023082.g001
Implications of Egr-1 Target Genes in SSc
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e23082of incubation, TGF-ß and Egr-1 modulated the expression of 158
and 647 genes, respectively, only 98 of these genes were regulated
simultaneously by both TGF-ß and Egr-1, with 83/98 genes
showing concordantly increased, and 15/98 genes showing
concordantly decreased, expression (Fig. 3A, and Table S3).
Ingenuity Pathway Analysis showed that these 98 concordantly-
regulated genes are implicated in cell cycle regulation, cell
proliferation, cellular assembly and organization, cellular function
and maintenance, cellular development and movement, and cell-
mediated immune responses (Fig. 3B).
The fibroblasts Egr-1-responsive gene signature in
scleroderma skin biopsies
To determine the clinical implications of activated Egr-1
signaling, we examined the fibroblast ‘‘Egr-1-responsive gene
signature’’ in scleroderma skin biopsies. For this purpose, a
genome-wide microarray dataset comprising biopsies of lesional
and non-lesional skin from patients with various forms of
scleroderma (dcSSc, lcSSc and localized) and healthy controls
was [15]. Data for each gene identified above as Egr-1-responsive
were extracted from the microarray dataset, and the samples were
ordered according to the intrinsic gene clustering described
previously [15]. A heatmap of the 75-biopsy microarray dataset
of scleroderma and healthy skin biopsies was generated (Fig. 4A),
with the Egr-1-regulated gene signature shown to the left. In each
sample, the level of enrichment with the ‘‘Egr-1-responsive
signature’’ was quantified by calculating the Pearson correlation
coefficients between the Egr-1 centroid and the gene expression
data (Fig. 4A, lower panel). As shown in Figure 4, biopsies
clustering in the diffuse-proliferation intrinsic subsets (blue and red
dendograms) showed significant enrichment with ‘‘Egr-1-respon-
Figure 2. Egr-1-induced transcriptional responses in skin fibroblasts. Dermal fibroblasts were infected with Ad-EGFP or Ad-Egr-1m (100
MOI). At the end of 24 or 48 h incubation, total RNA was isolated and subjected to genome-wide transcriptional analysis using Illumina Microarray
chips (A,B) or real-time qPCR (C). A. Heatmap of differentially expressed genes (FDR,0.01 and .2- fold-change) (48 h). The color represents the fold-
change of Egr-1 in comparison with the average of control sample (red=increased, green=decreased). Each row represents a probe and each
column represents one sample. Genes with similar changes in expression pattern compared to the control are clustered together for 24 and 48 h. B.
Comparing a subset of biological processes significantly enriched (p,0.001) with Egr-1-regulated genes at 24 and 48 h. The number in the plot
indicates the differentially expressed genes belonging to individual GO categories (row) at corresponding time point (column). The total number of
genes at each time point (column) is shown below the Table. The background color represents the statistical significance of a particular biological
process overrepresented in the differential gene list as estimated by Hyper-geometric test. C. Real-time qPCR. Results, normalized with GAPDH mRNA,
are the means 6 S.D. of triplicate determinations from a representative experiment.
doi:10.1371/journal.pone.0023082.g002
Figure 3. Genes regulated by both TGF-ß and AdEgr-1. Skin
fibroblasts were infected with Ad-EGFP or incubated with TGF-ß in
parallel for 48 h. Total RNA was subjected to microarray analysis using
Illumina chips. A. Venn diagrams of the genes regulated by TGF-ß and
Egr-1. Left, up-regulated genes; right, down-regulated genes. B.
Ingenuity Pathway Analysis showing canonical signaling pathways
enriched with 98 fibroblast genes regulated by both Egr-1 and TGF-ß.
The Y axis shows the pathway enrichment.
doi:10.1371/journal.pone.0023082.g003
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compared to all other samples (average Pearson correlation
20.100060.1238, p,1610
218). Interestingly, these intrinsic
subsets were found previously to be significantly enriched with
the ‘‘TGF-ß-responsive gene signature’’ [18], providing evidence
for the relationship between TGF-ß and Egr-1 signaling in skin
fibrosis. Assessment of the clinical features indicated that these SSc
patient subsets had higher Rodnan skin scores, and greater
frequency of lung involvement [18].
The expression of ‘‘Egr1-responsive signature’’ genes across
each of the intrinsic subsets is presented in Table S4. Genes whose
expression is suppressed by Egr-1 in fibroblasts and that show
reduced expression in a particular biopsy subset are shown in
green; and genes that are stimulated by Egr-1 in fibroblasts and
show enhanced expression in the biopsies are shown in red.
Analysis of these data indicate that 53% of Egr-1-regulated genes
showed a concordant direction of change (increase or decrease) in
the diffuse-proliferative subset of skin biopsies; in contrast, 14% of
Egr-1-regulated genes showed a concordant pattern of change in
expression in the fibroblasts and skin biopsies clustering with the
inflammatory intrinsic subset (S4).
Further analysis of the expression of Egr-1-regulated genes in
the microarray dataset showed that while most of the Egr-1-
regulated genes were strongly associated with the diffuse-
proliferative intrinsic biopsies subsets, a group of genes including
TIMP3, Nox4, syndecan, collagen X and collagen XI and WISP1
was prominent in the ‘‘inflammatory’ and ‘‘limited’’ subsets of skin
biopsies, and was not significantly changed in the ‘‘diffuse
proliferation’’ subsets (Fig. 4B–D).
Of the 98 genes coordinately regulated in fibroblasts by both
Egr-1 and TGF-ß, 73 were found to be present in the scleroderma
biopsy microarray dataset. The ‘‘diffuse-proliferation’’ intrinsic
subsets were substantially enriched with these genes which are
involved in cell cycle regulation and cell proliferation (Fig. S1 and
data not shown).
Expression of Egr-1 and target genes in SSc skin biopsies
The expression of Egr-1 in SSc was examined by immunohis-
tochemistry. For this purpose, skin biopsies from patients with
early dcSSc (,1 year) and age-matched healthy controls were
studied in parallel. The results showed that in contrast to control
biopsies that had little or no detectable Egr-1 in the dermis, in SSc
biopsies a significant proportion of fibroblastic cells, as well as
some vascular cells, showed distinct Egr-1 immunostaining
(Fig. 5A). In the epidermis, SSc samples and healthy controls
showed similar Egr-1 levels. The expression of selected Egr-1-
regulated genes was next examined. Immunohistochemistry
showed that COMP, an Egr-1-regulated ECM protein known to
be induced by TGF-b, was strongly expressed throughout the
dermis in SSc biopsies, but was sparse in control biopsies (Fig. 5A).
Figure 4. Expression of the Egr-1-responsive gene signature in SSc skin biopsies. A. Egr-1-responsive genes are aligned with the gene
expression data from dcSSc and healthy control skin biopsies. The samples were clustered using the 647 genes that comprise Egr-1-responsive gene
signature. Dendrogram shows clear differences in skin biopsies. The left branch of the dendogram (highlighted in red and blue), comprises solely
dcSSc biopsies clustering with the diffuse-proliferation intrinsic subsets (diffuse 1 and diffuse 2). The right branch includes remaining dcSSc samples,
as well as lcSSc, localized scleroderma and all healthy controls. Quantitation of Egr-1 signaling in each biopsy by Pearson correlation is shown below
the heatmap. B. Genes showing high expression in dcSSc skin biopsies and in Egr-1-expressing fibroblasts. C. Genes associated with the
inflammatory and normal-like intrinsic subsets, or low expression in proliferation subset and Egr-1-expressing fibroblasts. D. Genes showing low
expression in the proliferation subset but high expression in Egr-1-expressing fibroblasts and inflammatory subset.
doi:10.1371/journal.pone.0023082.g004
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(Sargent et al, JID), and is also regulated by Egr-1, was found to be
elevated in some fibroblasts in SSc skin biopsies but not in control
(Fig. 5B). E2F7 immunostaining was also seen in some vascular
cells and in keratinocytes in the SSc biopsies. Growth differenti-
ation factor-6 (GDF6), a member of the TGF-ß superfamily that is
also regulated by both TGF-b and Egr-1, was up-regulated in the
basal epidermis, dermal fibroblasts and in vascular cells in SSc skin
biopsies compared to control biopsies (Fig. 5C).
Discussion
We previously identified Egr-1 as a novel mediator of TGF-ß-
induced collagen stimulation that is up-regulated in skin and lung
biopsies of patients with SSc [7]. In this study, we investigated
genome-wide Egr-1 transcriptional responses in normal fibroblasts
by DNA microarray analysis. Egr-1 was shown to modulate the
expression of 647 genes that define the fibroblast ‘‘Egr-1-
responsive gene signature’’. This signature comprises genes
involved in cell proliferation and migration, ECM synthesis,
wound healing, and vascular development and shows only a
partial overlaps with TGF-ß-regulated gene signature. Important-
ly, this gene signature is highly expressed in skin biopsies from
subsets of dcSSc patients, but is not found in patients with lSSc, or
morphea, or in healthy controls.
In immortalized vascular endothelial cells, ectopic Egr-1 induced
the transcription of more than 300 genes [16]. These genes are
involved in transcriptional regulations, signaling, cell cycle, cytokines
and ECM biosynthesis. In normal skin fibroblasts, Egr-1 altered the
expression of a partially overlapping set of 647 genes involved in cell
proliferation, migration, ECM synthesis, wound healing, vascular
development and TGF-ß receptor signaling, suggesting cell type-
specific differences in Egr-1 transcriptional responses.
Rapid and generally transient Egr-1 induction is essential for
orchestrating acute tissue responses to various forms of injury [19].
Emerging evidence implicates Egr-1 in physiological wound healing
on one hand, and pathological tissue repair on the other [20]. We
found that the ECM genes collagen, biglycan, fibronectin, COMP,
and PLOD2 were up-regulated by Egr-1. Since Egr-1 is persistently
overexpressed in SSc skin and lung biopsies from SSc patients, it
might drive unchecked target gene activation resulting in fibrosis.In
particular, our results show a strong ‘‘Egr-1-responsive gene
signature’’ expression in the skin biopsies clustering with the
‘diffuse-proliferation’ SSc subset but not with biopsies from patients
with limited SSc or morphea, or healthy controls. This intrinsic SSc
subset was shown previously to be associated with a higher skin
scores and incidence of lung involvement [18].
Scleroderma is characterized by substantial patient-to-patient
heterogeneity in presentation, autoantibody profiles, clinical
outcome and molecular signatures [2]. DNA microarray analysis
of gene expression in skin biopsies provides evidence for distinct
subsets of scleroderma distinguishable by their gene expression
patterns [15]. The present results raise the possibility that dcSSc
patients expressing the ‘‘Egr-1 responsive gene signature’’
represent a distinct molecular subset whose disease is driven by
Egr-1, and who might therefore benefit from interventions
specifically targeting Egr-1. Several drugs in current clinical use
have potent effects on Egr-1 expression. These include mycophe-
nolate mofetil [21], cyclosporine [22], simvastatin [23], imatinib
mesylate [24] and insulin-sensitizing PPARc ligands such as
rosiglitazone [25,26]. In summary, the present results demonstrate
that persistent Egr-1 expression in normal fibroblasts induces
substantial genome-wide change in gene expression, with robust
up-regulation of wound healing and fibrogenic gene expression
program. A subset of skin biopsies from patients with dcSSc, but
not other forms of scleroderma, show evidence of robust Egr-1-
dependent gene activation. In view of the aberrant Egr-1 or its
signature gene expression seen in SSc and other forms of
pathological fibrosis, these results suggest that sustained Egr-1
signaling could be implicated in SSc fibrogenesis, and blocking
Egr-1 signaling pathway may be of therapeutic benefit in
controlling the progression of fibrosis.
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Figure 5. Expression of the Egr-1 and its target genes in SSc
skin biopsies. Immunohistochemistry. Skin biopsies from SSc patients
and healthy controls were immunostained with antibodies. Represen-
tative images. A. Egr-1. a healthy control, b–f SSc. (a–c original
magnification, 6100; d–f original magnification, 6400). B–D. COMP,
E2F7 and GDF6. a,c,e healthy controls; b,d,f SSc.(Original magnification
6400).
doi:10.1371/journal.pone.0023082.g005
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